Chief Executive Officer, George Medicines
| Role | Organisation | Sources |
|---|---|---|
| VicePresident and Global Franchise Head, Inflammatory Bowel Disease (IBD) (former) | Takeda Pharmaceuticals | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Novartis | Brandon BioCatalyst portfolio, Brandon Capital portfolio | |
| Merck | Brandon BioCatalyst portfolio, Brandon Capital portfolio | |
| Chief Executive Officer | George Medicines | Brandon BioCatalyst portfolio (Mon 12 Jul 2021), Brandon Capital portfolio (Mon 12 Jul 2021), Brandon BioCatalyst portfolio (Thu 1 Jul 2021), Brandon Capital portfolio (Thu 1 Jul 2021), Brandon BioCatalyst portfolio (Thu 3 Jun 2021), Brandon Capital portfolio (Thu 3 Jun 2021) |
Stories naming Stefan König. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
George Medicines, a George Institute spin-out developing combination blood pressure therapies, has appointed former CSL Behring chief medical officer Dr Charmaine Gittleson as an independent non-executive director as its drug GMRx2 enters Phase III trials.
Drug developer George Medicines has added Dr Charmaine Gittleson to its board as an independent non-executive director, bringing pharma and CSL Behring leadership experience as its hypertension candidate GMRx2 advances through Phase III trials.
George Medicines has begun two Phase III trials testing its triple-combination pill GMRx2 as a first-line hypertension treatment, with patient availability possible by 2023 pending US regulatory approval.
Drug developer George Medicines has started two Phase III trials of its GMRx2 triple-combination pill as a first-line hypertension therapy, enrolling patients across seven countries, with possible availability by 2023 pending US regulator approval.
Drug developer George Medicines has named Stefan König, previously a senior Takeda executive, as its chief executive, while chief business officer Karl Roberts moves into the chief operating officer role.
George Medicines has named Stefan König, previously a Takeda franchise head, as its new CEO, while Karl Roberts moves from Chief Business Officer to Chief Operating Officer. The company also announced US FDA clearance to begin Phase III trials of GMRx2.